Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis

International Journal of Infectious Diseases

Volumn 65, Issue , 2017, Pages 135-141

  Lee, Hyun ^a   Ahn, Soohyun ^b   Hwang, Na Young ^b   Jeon, Kyeongman ^a   Kwon, O Jung ^a   Huh, Hee Jae ^a   Lee, Nam Yong ^a   Koh, Won Jung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Extensively drug resistant tuberculosis; Multidrug resistant tuberculosis; Rifabutin; Treatment outcome

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTHRALGIA; ARTICLE; BODY MASS; CHRONIC LIVER DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYALGIA; NEUTROPENIA; PRURITUS; RETROSPECTIVE STUDY; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INFECTION; LUNG TUBERCULOSIS; MIDDLE AGED; MULTIDRUG RESISTANCE;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFABUTIN; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85037706364     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2017.10.013     Document Type: Article

References (29)

1. Ahuja, S.D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J.N., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med, 9, 2012, e1001300.
2. Bai, G.H., Park, Y.K., Choi, Y.W., Bai, J.I., Kim, H.J., Chang, C.L., et al. Trend of anti-tuberculosis drug resistance in Korea, 1994–2004. Int J Tuberc Lung Dis 11 (2007), 571–576.
3. Bastos, M.L., Lan, Z., Menzies, D., An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J, 49, 2017 1600803.
4. Berrada, Z.L., Lin, S.Y., Rodwell, T.C., Nguyen, D., Schecter, G.F., Pham, L., et al. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis 85 (2016), 177–181.
5. Cavusoglu, C., Karaca-Derici, Y., Bilgic, A., In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 10 (2004), 662–665.
6. Chang, K.C., Yew, W.W., Tam, C.M., Leung, C.C., WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 57 (2013), 4097–4104.
7. Chien, H.P., Yu, M.C., Ong, T.F., Lin, T.P., Luh, K.T., In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan. J Formos Med Assoc 99 (2000), 408–411.
8. Dheda, K., Gumbo, T., Maartens, G., Dooley, K.E., McNerney, R., Murray, M., et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 5 (2017), 291–360.
9. Dheda, K., Limberis, J.D., Pietersen, E., Phelan, J., Esmail, A., Lesosky, M., et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med 5 (2017), 269–281.
10. Dickinson, J.M., Mitchison, D.A., In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 68 (1987), 177–182.
11. Dooley, K.E., Obuku, E.A., Durakovic, N., Belitsky, V., Mitnick, C., Nuermberger, E.L., World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential. J Infect Dis 207 (2013), 1352–1358.
12. Falzon, D., Schunemann, H.J., Harausz, E., Gonzalez-Angulo, L., Lienhardt, C., Jaramillo, E., et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J, 49, 2017, 1602308.
13. Fox, G.J., Benedetti, A., Cox, H., Koh, W.J., Viiklepp, P., Ahuja, S., et al. Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J, 49, 2017 1600993.
14. Gler, M.T., Skripconoka, V., Sanchez-Garavito, E., Xiao, H., Cabrera-Rivero, J.L., Vargas-Vasquez, D.E., et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366 (2012), 2151–2160.
15. Grassi, C., Peona, V., Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 22:Suppl. 1 (1996), S50–S54.
16. Jamieson, F.B., Guthrie, J.L., Neemuchwala, A., Lastovetska, O., Melano, R.G., Mehaffy, C., Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 52 (2014), 2157–2162.
17. Jeon, D., Medical management of drug-resistant tuberculosis. Tuberc Respir Dis (Seoul) 78 (2015), 168–174.
18. Jeong, B.H., Jeon, K., Park, H.Y., Kwon, O.J., Lee, K.S., Kim, H.K., et al. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment. J Antimicrob Chemother 70 (2015), 3127–3133.
19. Jo, K.W., Ji, W., Hong, Y., Lee, S.D., Kim, W.S., Kim, D.S., et al. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med 107 (2013), 292–297.
20. Lee, C.N., Lin, T.P., Chang, M.F., Jimenez, M.V., Dolfi, L., Olliaro, P., Rifabutin as salvage therapy for cases of chronic multidrug-resistant pulmonary tuberculosis in Taiwan. J Chemother 8 (1996), 137–143.
21. Nahid, P., Dorman, S.E., Alipanah, N., Barry, P.M., Brozek, J.L., Cattamanchi, A., et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 63 (2016), e147–95.
22. Rigouts, L., Gumusboga, M., de Rijk, W.B., Nduwamahoro, E., Uwizeye, C., de Jong, B., et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 51 (2013), 2641–2645.
23. Senol, G., Erbaycu, A., Ozsoz, A., Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother 17 (2005), 380–384.
24. Sirgel, F.A., Warren, R.M., Bottger, E.C., Klopper, M., Victor, T.C., van Helden, P.D., The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One, 8, 2013, e59414.
25. Telenti, A., Imboden, P., Marchesi, F., Lowrie, D., Cole, S., Colston, M.J., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341 (1993), 647–650.
26. Uzun, M., Erturan, Z., Ang, O., Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 6 (2002), 164–165.
27. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO. http://www.who.int/tb/publications/pmdt_companionhandbook/en/. [Accessed 1 March, 2017].
28. World Health Organization. Definitions and reporting framework for tuberculosis—2013 revision. WHO/HTM/TB/2013.2. Geneva, Switzerland: WHO. http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf. [Accessed 1 March 2017].
29. World Health Organization, Guidelines for the progammatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO. http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf. [Accessed 1 March 2017].